MedTrace Logo

A Phase 2 Study of CIN-102 in Adults With Idiopathic and Diabetic Gastroparesis

NCT04026997 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2026-03-25

Study results available
· View outcomes & findings →

Summary

This is a randomized, double-blind, placebo-controlled Phase 2A study to evaluate safety, efficacy, PK, and dose response of oral CIN-102 in adults with idiopathic and diabetic gastroparesis. The study will assess three oral doses of CIN-102 versus placebo in three separate cohorts.

Conditions

Interventions

DRUG

CIN-102 Dose 1

CIN-102 Dose 1

DRUG

CIN-102 Dose 2

CIN-102 Dose 2

DRUG

CIN-102 Dose 3

CIN-102 Dose 3

DRUG

Placebo

Placebo

Sponsors & Collaborators

  • CinDome Pharma, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-09-11
Primary Completion
2020-12-17
Completion
2020-12-17
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04026997 on ClinicalTrials.gov